ECTRIMS 2021: Satralizumab Maintains Efficacy Long-Term in AQP4-IgG+ NMOSD
Patients remained free of relapse, severe relapse, or worsening disease over >3.5 years.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.